Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.70 |
| ▸ | NPBWR1 | P48145 | 14/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PKLR | P30613 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18979972 | 0.87 | POLB (0.59) | POLBSMN1; SMN2MEN1RAB9ABLM | |
| SCHEMBL4178364 | 0.85 | ALDH1A1 (0.62) | POLBSMN1; SMN2MEN1RAB9ABLM | |
| SCHEMBL19000729 | 0.84 | NPBWR1 (0.72) | POLBSMN1; SMN2MEN1RAB9ABLM | |
| SCHEMBL2180167 | 0.83 | KMT2A (0.61) | POLBSMN1; SMN2MEN1RAB9ABLM | |
| SCHEMBL10642561 | 0.83 | RAB9A (1.00) | POLBSMN1; SMN2MEN1RAB9ABLM | |
| SCHEMBL18979930 | 0.82 | NPSR1 (0.76) | POLBSMN1; SMN2MEN1RAB9ABLM | |
| SCHEMBL18980164 | 0.79 | RAB9A (0.76) | POLBSMN1; SMN2MEN1RAB9ABLM | |
| SCHEMBL14844510 | 0.78 | NPBWR1 (0.67) | SMN1; SMN2RAB9ANPSR1NPBWR1PKM | |
| SCHEMBL17099741 | 0.77 | MEN1 (0.73) | POLBSMN1; SMN2MEN1RAB9ABLM | |
| SCHEMBL981480 | 0.76 | KMT2A (0.54) | SMN1; SMN2MEN1RAB9AKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170173008-A1 | ANTIMICROBIAL AGENTS AND SCREENING METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173008-A1 | ANTIMICROBIAL AGENTS AND SCREENING METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173008-A1 | ANTIMICROBIAL AGENTS AND SCREENING METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173008-A1 | ANTIMICROBIAL AGENTS AND SCREENING METHODS | BAK1, DCLRE1B, BLVRB | POLB 11/4885SMN1; SMN2 4088/4885MEN1 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.